Immunservice GmbH develops biomimetic immune hormones, in particular interleukin-2, for safer, more effective and potentially curative therapies, especially in cancer.
Prof. Dr. Edith Huland
Dr. Michael Otto Invests in Innovate Immunotherapy to Prevent and Eliminate Cancer and Viral Infections
Immunservice GmbH has concluded a new round of financing (Series C) to secure development of the company’s biological immunotherapy methods for the long term. Joining the existing consortium of investors comprised of Helmut Ponath, the Hubertus-Wald-Stiftung, the High-Tech-Gründerfonds (HTGF) and Hartwig Huland…
20. Jul 2007